Nurix pushes its degrader forward
The company will start its confirmatory bexobrutideg study in June.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
Gyre picks up Cullgen for its degraders
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
No differentiation for Roche's degrader
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
